CyFlow CD106 Biotin
| 品番 | CX097139 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD106 BIOTIN,STA | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 Biotin (AQ807476) |
||
| 反応性|交差吸着 | Human | レーザー | |
| 抗原 | CD106, VCAM-1, INCAM-110 | 最大蛍光波長 | - |
| クローン | STA | 最大励起波長 | - |
| ホスト | Mouse | 標識/Format | Biotin |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD106 BIOTIN,STA
特異性
The mouse monoclonal antibody STA recognizes CD106 antigen, a 100-110 kDa type I membrane protein of the immunoglobulin superfamily, a crucial mediator of leukocyte adhesion, and a costimulation molecule.
抗原情報
CD106 (VCAM-1; vascular cell adhesion molecule-1) is an Ig-like cell surface adhesion molecule binding VLA-4 integrin. VCAM-1 is a potent T cell costimulatory molecule taking part in their positive selection and survival, as well as in adhesion, transendothelial migration and activation of peripheral T cells. VCAM-1 is also involved in endothelial cell-cell contacts. Whereas VCAM-1 normally mediates leukocyte extravasion to sites of tissue inflammation, tumor cells can use overexpressed VCAM-1 to escape T cell immunity. Soluble form of VCAM-1 (sVCAM-1) is an inflammatory marker and can be used also in prognosis of subsequent cariovascular events following acute coronary syndromes.
利用方法
The reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working usage is 8 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Leca G, Mansur SE, Bensussan A: Expression of VCAM‑1 (CD106) by a subset of TCR gamma delta‑bearing lymphocyte clones: Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform. J·Immunol. 1995·Feb·1; 154(3):1069‑77. <·PMID:·7529789·>
• Paessens LC, Singh SK, Fernandes RJ, van Kooyk Y: Vascular cell adhesion molecule‑1 (VCAM‑1 and intercellular adhesion molecule‑1 (ICAM‑1 provide co‑stimulation in positive selection along with survival of selected thymocytes. Mol·Immunol. 2008·Jan; 45(1):42‑8. <·PMID:·17604837·>
• Postadzhiyan AS, Tzontcheva AV, Kehayov I, Finkov B: Circulating soluble adhesion molecules ICAM‑1 and VCAM‑1 and their association with clinical outcome, troponin T and C‑reactive protein in patients with acute coronary syndromes. Clin·Biochem. 2007·Sep·19; <·PMID:·23105687·>
• van Wetering S, van den Berk N, van Buul JD, Mul FP, Lommerse I, Mous R, ten Klooster JP, Zwaginga JJ, Hordijk PL: VCAM‑1‑mediated Rac signaling controls endothelial cell‑cell contacts and leukocyte transmigration. Am·J·Physiol·Cell·Physiol. 2003·Aug; 285(2):C343‑52. <·PMID:·12700137·>
• Wu TC: The role of vascular cell adhesion molecule‑1 in tumor immune evasion. Cancer·Res. 2007·Jul·1; 67(13):6003‑6. <·PMID:·17616653·>
• Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA: Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J·Virol. 2006·Mar; 80(6):2684‑93. <·PMID:·16501078·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN